This study was conducted to determine species differences in the metabolism of ethylbenzene (EB) in liver and lung. EB (0.22-7.0mM) was incubated with mouse, rat and human liver and lung microsomes and the formation of 1-phenylethanol (1PE), acetophenone (AcPh), 2-ethylphenol (2EP), 4-ethylphenol (4EP), 2,5-ethylquinone, and 3,4-ethylquinone were measured. Reactive metabolites (2,5-dihydroxyethylbenzene-GSH [2EP-GSH] and 3,4-dihydroxyethylbenzene-GSH [4EP-GSH]) were monitored via glutathione (GSH) trapping technique. None of the metabolites were formed at detectable levels in incubations with human lung microsomes. Percent conversion of EB to 1PE ranged from 1% (rat lung; 7.0mM EB) to 58% (mouse lung; 0.22mM EB). More 1PE was formed in mouse lung than in mouse liver microsomes, although formation of 1PE by rat liver and lung microsomes was similar. Metabolism of EB to 1PE was in the order of mouse > rat > human. Formation of AcPh was roughly an order of magnitude lower than 1PE. Conversion of EB to ring-hydroxylated metabolites was much lower (0.0001% [4EP-GSH; rat lung] to 0.6% [2EP-GSH; mouse lung]); 2EP-GSH was typically 10-fold higher than 4EP-GSH. Formation of 2EP-GSH was higher by lung (highest by mouse lung) than liver microsomes and the formation of 2EP-GSH by mouse liver microsomes was higher than rat and human liver microsomes. Increasing concentrations of EB did lead to a decrease in amount of some formed metabolites. This may indicate some level of substrate-or metabolite-mediated inhibition. High concentrations of 2EP and 4EP were incubated with microsomes to further investigate their oxidation to ethylcatechol (ECat) and ethylhydroquinone (EHQ). Conversion of 2EP to EHQ ranged from 6% to 9% by liver (mouse > human > rat) and from 0.1% to 18% by lung microsomes (mouse >> rat >> human). Conversion of 4EP to ECat ranged from 2% to 4% by liver (mouse > human~rat) and from 0.3% to 7% by lung microsomes (mouse >> rat >> human). Although ring-oxidized metabolites accounted for a relatively small fraction of overall EB metabolism, its selective elevation in mouse lung microsomes is nonetheless consistent with the hypothesized mode of action for observed preferential toxicity of EB to the lung in this species.
Ethylbenzene (EB) is commonly used as an intermediate in the manufacture of styrene and synthetic rubber. It is also present in agricultural and home insecticide sprays, household degreasers, paints, adhesives, rust preventives, and as a major component of mixed xylenes used as a solvent. Occupational exposure to EB may occur during the production of polystyrene as well as during production and use of mixed xylenes (Fishbein, 1985) .
EB induces tumors in rats and mice (NTP, 1999) and has been categorized as a group 2B carcinogen (possibly carcinogenic to humans) by the International Agency of Research on Cancer (IARC, 2000) . In an inhalation carcinogenicity study in which F344/N rats and B6C3F1 mice were exposed to 0, 75, 250, or 750 ppm EB 6 h/day, 5 days/week, for 104 weeks, carcinogenic activity has been reported (NTP, 1999) . Statistically significant neoplastic changes in the NTP (1999) study included: renal tubule adenomas in high exposure group male and female rats (changes to female kidney were noted only after step-sectioning), lung alveolar/bronchiolar adenomas in high exposure group male mice (and intermediate exposure group when combined with carcinomas), and liver adenomas in high exposure group female mice. However, no statistically significant increases in tumors were reported in Sprague-Dawley rats gavaged with 500 mg/kg/day EB (4-5 days/week, for 104 weeks) (Maltoni et al., 1985) . Chen et al. (2008) assessed the genotoxicity of a number of compounds (methyl-tert-butyl ether, benzene, toluene, EB, and xylene) in human lymphocytes using comet assay and found that EB failed to cause genotoxicity even at a very high concentration (200lM) . Also, Norppa and Vainio (1983) while evaluating styrene analogs (2-methylstyrene, 3-methylstyrene, 4-methystyrene, 3,5-dimethystyrene, a-methylstyrene, trans-bmethylstyrene, EB, 2-phenylethanol, 4-methylstyrene oxide, 3,5-dimethylstyrene oxide, 4-nitrostyrene oxide, and styrene) reported that EB itself does not induce sister-chromatid exchanges after 48 h of treatment of human lymphocytes and only marginal effects could be induced at the highest tested dose of 10mM. They also suggested that EB itself is not an effective mutagen prior to its conversion to reactive species (Norppa and Vainio, 1983) . Henderson et al. (2007) have recently reviewed the currently available in vivo and in vitro genotoxicity data of EB and concluded that EB does not induce kidney, liver or lung tumors in rat and mice through a genotoxic mechanism.
EB has not been reported to cause genotoxicity in workers exposed to relatively high levels of EB at workplace (84-539 ppm and for some higher than 921 ppm EB) (Holz et al., 1995) . Similarly, in two epidemiological studies no excess cancer incidence or mortality due to cancer was observed in workers potentially exposed to EB in a production plant and a styrene polymerization plant and followed for extended period of time, in one study up to 15 years (IARC, 2000) .
The principle metabolic pathway of EB in humans and rats is alkyl-oxidation to 1-phenylethanol (1PE) and subsequent alkyloxidized products ( Fig. 1 ) (Charest-Tardif et al., 2006; Engstrom, 1984) . In addition, Midorikawa et al. (2004) demonstrated the potential for EB ring-oxidation to mono-and dihydroxylated metabolites (e.g., and downstream metabolites [hydroquinone and catechol]) ( Fig. 1) , a pathway consistent with studies demonstrating similar metabolism of the structurally analogous compound styrene, to 4-vinylphenol (Bartels et al., 2005) . Formation of ring-oxidized metabolite(s) may likely be the key to EB-induced mouse-specific lung toxicity (Fig. 1) , in that the mouse lung toxicity of styrene has also been linked to mouse-specific cytochrome P450 CYP 2F2 ring-oxidation metabolism (Cruzan et al., 2002) . EPs have been reported to cause direct pneumotoxicity in mice (Gelbke, personal communication, 2005) . Because 2EP and 4EP have no structural alerts indicating carcinogenic potential, these findings suggest the subsequent formation of ring-oxidized metabolites (hydroquinone and catechol) of EB are involved in causing mouse specific lung tumors. Therefore, this study was designed to determine the potential of mouse, rat and human lung and liver microsomes to metabolize EB to 2EP and 4EP, their downstream metabolism to 2,5-dihydroxyethylbenzene and 3,4-dihydroxyethylbenzene, and ultimately to the reactive quinones (2, 5EQ], and 3, 4EQ] ). Additionally, rates of the formation of 1PE, acetophenone (AcPh), and glutathione (GSH)-trapped quinone metabolites from EB (2,5-dihydroxyethylbenzene-GSH [2EP-GSH] and 3,4-dihydroxyethylbenzene-GSH [4EP-GSH]) were also determined from liver and lung microsomes of the three species.
MATERIALS AND METHODS
Chemicals. EB, 1PE, 2-phenylethanol (2PE), 2EP, 4EP, AcPh, ECat) , ethylhydroquinone (2,5-dihydroxyethylbenzene, EHQ), and 4-ethylresorcinol of ! 99% purity were purchased from Sigma-Aldrich (St Louis, MO), Indofine (Hillsborough, NJ), or Alfa Aesar (Ward Hill, MA). Tritiated glutathione ( 3 H-GSH) was purchased from Perkin Elmer Life and Analytical Sciences (Boston, MA). Deuterated internal standards (d 10 -EB, d 5 -1PE, d 5 -AcPh, d 4 -GSH) and other reagents were purchased from Sigma-Aldrich Chemical. All other solvents and reagents were purchased from VWR International (West Chester, PA) of the highest purity available.
Tissue types and source/supplier. Metabolism of EB and its metabolites was conducted using liver and lung microsomes obtained from un-induced male Fischer-344 rats, male B6C3F1 mice, and humans of mixed gender and race. Microsomes were obtained from XenoTech (Lenexa, KS). Rat liver and lung microsomes were prepared from pools of 15 and 100 untreated animals, respectively. Mouse liver and lung microsomes were prepared from pools of 126 and 100 animals, respectively. Human liver microsomes were from a pool of 50 individuals of mixed gender, race (Caucasian, African, and Hispanic) and age (6-78 years old with most of them between 30 and 50 years); 31 of them died from cerebrovascular stroke, 12 from head trauma, five from anoxia, one from myocardial infarction, and one from aortic aneurysm. Human lung microsomes of nonsmokers were prepared from a pool of four individuals of mixed gender (three males; one female), one died from stroke, one from interacranial hemorrhage, one from drug overdose, and one from motor vehicle accident. Microsomes were received in small aliquots on dry ice and stored at À80°C. Each microsomal preparation was analyzed for CYP1A1, CYP2B1 and CYP2E1 activities. Liver microsomes contained 0.79 (mouse), 0.93 (rat), and 0.36 (human) nmol cytochrome P450/mg protein.
Synthesis of the GSH conjugates of 2,5EQ (2EP-GSH) and 3,4EQ (4EP-GSH). Standards of 2EP-GSH and 4EP-GSH were prepared by reacting 3 H-GSH and 2EP or 4EP. The incubation conditions employed for these preparations were the same as described for the microsomal metabolism of EB below. Concentrations of either substrate were 1mM, with 5mM 3 H-GSH (30-min incubations). After the completion of the incubations, samples were filtered through 0.2-lm syringe filter (13-mm ZC PTFE, Whatman, Florham Park, NJ) and the filtrates analyzed by reverse-phase high performance liquid chromatography (HPLC)/electrospray tandem mass spectrometry (ESI-MS/ MS) with an Applied Biosystem Sciex API 3000 tandem mass spectrometer (Concord; Ontario, Canada) equipped with an Agilent (Agilent Technologies, Inc., Santa Clara, CA) HP 1100 HPLC system (C 18 column). The mass spectrometer was equipped with a TurboIonspray interface. The mobile phase was comprised of deionized water þ 0.1% acetic acid (A) and acetonitrile þ 0.1% acetic acid (B); gradient of B was ramped from 5% to 40% at 2.7%/min and then to 95% at 6.0%/min. The total run time was 21 min. The formed GSH conjugate standards were confirmed by HPLC-RAM (radioactive detector) in addition to the widely used HPLC/ESI-MS/MS approach (Moridani et al., 2002; Yu et al., 2004; Zhang et al., 2000 Zhang et al., , 2001 . Based on the radioactivity, the concentration of each GSH conjugate standard was also determined.
Part I: microsomal metabolism of EB vapors. Part I experiments were conducted to determine difference in the metabolism of EB by liver and lung microsomes of the three species when introduced as vapor. Two concentrations (750 and 7500 ppm) of EB vapor in air were incubated in triplicate with microsomes (2 mg protein in 2 ml of reaction mixture, 0.1M phosphate buffer, 1mM nicotinamide adenine dinucleotide phosphate, reduced [NADPH] , pH 7.4) in 25-ml gas-tight glass vials. The Tedlar bags containing each concentration of EB vapors were prepared by drawing a known volume of charcoal-filtered air through a heated J-tube containing EB. The concentration of EB in each Tedlar bag was confirmed by gas chromatography/flame ionization detector (GC/FID) using a 30 m 3 0.32 mm capillary column (HP-5; 0.25 lm film). The injector and detector temperature was 250°C, oven temperature was programmed from 50°C (1 min) to 150°C (at 15°C/min). The carrier and makeup gas was nitrogen at 30 ml/min; the injection volume was 1 ll.
To prepare the incubations, microsomes and buffer containing NADPH were placed in vials and sealed with open-hole screw-caps fitted with Teflon/ silicone septa. Approximately 150 ml of EB vapor was drawn from the Tedlar METABOLISM OF EB BY RAT MOUSE AND HUMAN 353 bags into an airtight Hamilton syringe and the headspace of the vials containing reaction mixtures were purged. The~150 ml of vapor was enough for five to six air exchanges of the headspace. The vials were placed in a shaking water bath immediately after purging the headspace with EB vapors and incubated for 30 min at 37°C. After 30 min, the vials were removed from the incubator and immediately placed on dry ice to condense EB vapors and also to stop metabolic reaction. Once the reaction mixture was frozen, 2 ml of carbon disulfide (CS 2 ) was injected through the septum-lined caps, the vials were rolled to extract EB from the sides and 200 ll of an aqueous formic acid:ascorbic acid (10:20%, vol/vol) mixture was injected. The vials were kept at À80°C overnight, allowed to thaw at room temperature and shaken for 30 min at low speed on a flatbed shaker. The CS 2 layer was removed and remaining water was dried over~200 mg MgSO 4 and analyzed for EB, 1PE, 2PE, 2EP, 4EP, and AcPh using GC/FID as described above.
Two types of controls were also incubated: one (buffer, microsomes, and reagents without substrate [EB] ) to confirm that no background peaks appear in the region of the substrate (EB) and metabolites of interest, and the other control (buffer, microsomes, and substrate [7500 ppm EB] without NADPH) to determine nonenzymatic conversion of the substrate (EB) to the metabolite(s) of interest. Recovery of each metabolite was determined from the liver and lung microsomal incubations by injecting known amounts of metabolites (contained as a mixture within the acidic solution) into the vials containing microsomes, buffer, reagents, without EB, immediately after the completion of incubation and freezing on dry ice. Extraction and analysis of the samples were same as described above. The recoveries were used to correct the measured concentrations to the actual amount of each metabolite formed. Recoveries of metabolites from the liver microsomal incubations were 71, 92, 63, 88, and 77 percent for 1PE, AcPh, 2PE, 2EP, and 4EP, respectively. Recoveries of metabolites from the lung microsomal incubations were 73%, 98%, 67%, 90%, and 79% for 1PE, AcPh, 2PE, 2EP, and 4EP, respectively. Total recovery of the incubated EB (EB þ metabolites), after correction for the loss from incubates containing no NADPH, from liver microsomal incubates was 100 ± 11% and from lung microsomal incubates was 91 ± 21%.
Part II: microsomal metabolism of 2EP and 4EP. Part II experiments were conducted to determine the difference in the metabolism of two of the reactive metabolites (metabolism 2EP and 4EP to EHQ and ECat, respectively) of EB between liver and lung microsomes and among three species. One concentration of 2EP or 4EP (1mM; ! 100-fold higher than the levels of these metabolites formed from EB in Part I for ease in analytical quantification of EHQ and ECat, if formed) was incubated in triplicate for 30 min at 37°C with microsomes (2 mg protein in 2 ml of reaction mixture, 0.1M phosphate buffer, 1mM NADPH, pH 7.4) in 24-ml gas-tight glass vials. Two types of controls (with and without substrates or NADPH), as described above, were also incubated. After the completion of the incubations, samples were filtered through 0.2-lm syringe filter and analyzed for the loss of 2EP and 4EP and the formation of EHQ and ECat by Agilent HP 1100 HPLC (C 18 column) equipped with UV detector (wavelength ¼ 222 nm). The mobile phase was comprised of Milli-Q water (A) and methanol (B); gradient of B was kept at 55% from 0 to 15 min and then ramped to 80% and maintained from 16 to 18 min.
For comparison with the results of the Part I experiments, mouse liver and lung microsomes were incubated with 750 lg (7mM) of EB (introduced to incubation solution containing microsomes [2 mg protein in 2 ml of reaction mixture], 0.1M phosphate buffer and 1mM NADPH at the pH of 7.4, in propylene glycol [PG] ). The 750 lg EB was equivalent to the amount of EB vapors in the headspace of vials incubated with 7500 ppm EB vapor in the Part I experiment. After completion of 30-min incubations, samples were analyzed for the formation of 1PE, 2EP, 4EP, as well as EHQ and ECat using highperformance liquid chromatography/ultraviolet technique as described above. The formation of EHQ and ECat could not be determined in the Part I experiment due to the use of gas chromatography.
Part III: rate of microsomal metabolism of EB to 1PE, AcPh, and quinones. Part III experiments were conducted to determine the kinetics of microsomal conversion of EB to 1PE, AcPh, 2,5EQ (via intermediate metabolites 2EP and EHQ), 3,4EQ (via intermediate metabolites 4EP and ECat). A probe experiment indicated that the rate of formation of all four metabolites was linear for at least 30 min (data not shown). Therefore, a 30-min incubation period was used in the kinetic experiments.
For the definitive kinetics experiments, mixtures of microsomes (2 mg protein in 2 ml of reaction mixture), buffer (0.1M phosphate), NADPH (1mM), and GSH (10mM) were incubated in triplicate at 37°C with EB (in 10 ll of PG) at six concentrations (0.22, 0.45, 0.9, 1.8, 3.5, and 7.0mM) for 30 min. Three types of controls (1 [no EB] ¼ buffer, 1mM NADPH, microsomes, GSH, 10 ll of PG; 2 [no cofactors] ¼ buffer, microsomes, GSH, 10 ll of PG, EB [0.45, 1.8, or 7.0mM]; 3 [no microsomes] ¼ buffer, 1mM NADPH, GSH, 10 ll of PG, EB [0.45mM]) were also incubated to determine the possible interfering peaks in the areas of interest and the potential for nonenzymatic conversion.
Following incubation, each solution was processed for two types of analyses. The first analysis (by GC/MS) was conducted to determine major metabolites (1PE and AcPh) of EB. The second analysis utilized a GSH trapping technique (Bartels et al., 2005) in which reactive metabolites of EB (e.g., quinones of EHQ or ECat), if formed, were reacted with excess GSH present in the incubation mixture to form the GSH conjugates. The GSH conjugates, referred 2EP-GSH and 4EP-GSH, were analyzed by HPLC with multiple reaction monitoring mass spectrometry (HPLC/MRM/MS), similar to that described above in the section detailing synthesis of GSH conjugates and widely used for the determination of the conjugated quinones and catechols (Moridani et al., 2002; Yu et al., 2004; Zhang et al., 2000 Zhang et al., , 2001 . The pathways of the formation of GSH conjugates are
At the end of the 30-min incubation, metabolic reactions were stopped by injecting 0.2 ml of a mixture (2% formic acid, 5% ascorbic acid, and internal standards in 20:80 H 2 O:acetonitrile [vol/vol] ) through the septum of the sealed vials, which were then placed on an ice bath before opening the caps. The internal standards contained in the acidic solution were d 10 -EB, d 5 -1PE, and d 5 -AcPh (600 lg/ml each in the acidic solution). The precipitated proteins were removed by filtering the mixtures through 0.2-lm syringe filters and the filtrates collected. For the analysis of EB, 1PE, and AcPh, aliquots of the filtrate were extracted with CS 2 and transferred to vials containing MgSO 4 to remove remaining water. Analytes in the CS 2 extracts were determined by GC/Electron Impact/MS (1 ll split [16:1] injection) using a Phenomenex ZB-5ms capillary column (30 m 3 0.25 mm, 0.5 lm film). The injection port temperature was 250°C; transfer line temperature was 280°C; oven temperature programmed from 80°C (1 min) to 140°C at 10°C/min and then ramped to 200°C at 25°C/min. The GC/EI/MS was in positive ionization mode. For the analysis of reactive metabolites (2EP-GSH and 4EP-GSH), laboratory-synthesized internal standard (d 4 -4EP-GSH) was added to aliquots of the microsomal incubation filtrate and analyzed by HPLC/MRM/MS, similar to that described above in the section detailing synthesis of GSH conjugates.
Data analysis. Data are presented as mean ± standard deviation for the depletion of parent EB and formation of metabolites. The rates of metabolism were calculated using standard methods (e.g., Eadie-Hofstee, LineweaverBurk plots).
RESULTS

Part I: Microsomal Metabolism of EB Vapor in Headspace
Recovery of metabolites from the incubates. Recovery of each of the metabolites (1PE, 2PE, AcPh, 2EP, and 4EP) from the rat liver and lung microsomes was very consistent ranging from 71% to 92% from liver microsomes and 73% to 98% from lung microsomes with the exception of 2PE, which was 63% and 67% from liver and lung microsomes, respectively (data not shown). These recoveries were used to calculate the actual amount formed during the incubations. Representative GC/FID chromatograms are shown in Figure 2 .
Metabolism of EB by rat, mouse, and human liver microsomes. 1 PE was the major metabolite of EB formed after 30 min of liver microsomal incubation (Table 1) . At the low concentration, mouse liver converted 19% of EB to 1PE; conversion at the high concentration was 3%. Human liver microsomes were also active in metabolizing EB to 1PE, converting 9 and~2% at the low and high concentrations, respectively. Metabolism of EB to 1PE by rat liver microsomes was 7 and 2% at the low and high concentrations, respectively. AcPh was detected only in rat liver microsomes at both of the concentrations (0.7% and 0.1% conversion at METABOLISM OF EB BY RAT MOUSE AND HUMAN 355 low and high concentrations, respectively) and only at the low concentration (1.7% conversion) in mouse liver microsomes. Formation of 2PE, 2EP, 4EP, and AcPh was detected in either very low amount or remained below the limit of quantification.
Metabolism of EB by rat, mouse, and human lung microsomes. In contrast to liver, human lung microsomes did not metabolize EB; levels of all of the targeted metabolites remained below the limit of detection of 0.5-0.7 nmol/ incubation mixtures (Table 2) . Similar to liver, 1PE was the major metabolite of EB detected after 30 min of incubation in both rat and mouse lung microsomes. At the low and high concentrations, mouse lung converted 19% and 5% of EB to 1PE, respectively. Metabolism of EB to 1PE by rat lung microsomes was 11% and 2% at the low and high concentrations, respectively. Conversion of EB to AcPh was detected in mouse lung microsomes at approximately 4-fold higher concentrations than mouse liver; whereas conversion of EB to AcPh by rat lung microsomes was comparable to the liver microsomes (Tables 1 and 2 ). Lung microsomes of rat and mouse were more active than liver microsomes in converting EB to 2PE. Detectable levels of 4EP were formed only in the mouse lung microsomes at the high concentration; others remained below the limit of quantification (Table 2) .
Part II: Microsomal Metabolism of 2EP and 4EP
Microsomal metabolism of 2EP and 4EP to dihydroxyethylbenzenes. The Part I experiments were structured to determine conversion of EB to the major primary monohydroxylated metabolites (i.e., 1PE, 2PE, AcPh, 2EP, 4EP) and not designed to characterize further downstream oxidative metabolism of mono-dihydrooxylated metabolites (i.e., 2EP and 4EP) to ring-hydroxylated metabolites (i.e., 2EP to EHQ and 4EP to ECat). Part II experiments were conducted to determine metabolism of 2EP and 4EP by rat, mouse, and human liver and lung microsomes and compare the difference in the formation of reactive metabolites of EB between liver and lung microsomes among the three species from these two minor phenolic metabolites. The results of the microsomal metabolism of 2EP and 4EP to EHQ (2,5-DiOHEB) and ECat (3,4-DiOHEB) are shown in Figures 3A and 3B , respectively. In general a higher percent conversion was observed in the metabolism of 2EP to EHQ compared with the conversion of 4EP to ECat. The highest conversion occurred in incubations with mouse lung microsomes for both metabolic pathways; approximately 18% of the 2EP was metabolized to EHQ and 7% of the 4EP was metabolized to ECat. Human lung microsomes were also active in metabolizing 2EP and 4EP as was evident from the loss of substrate, although almost none oxidized to EHQ or ECat (Fig. 3) . For the liver microsomes, the highest percent conversion of EB to EHQ and ECat again occurred with mouse liver microsomes. Compared across tissue types, the percent conversion from mouse lung incubations was roughly twofold greater than the conversion obtained from incubations with mouse liver microsomes. The percent conversion was approximately equivalent in incubations with rat lung and liver tissues. Human liver microsomes converted more of the EPs to the corresponding dihydroxyethylbenzene; equivalent to the rat liver microsomes. Between the two pathways, human liver microsomes formed about threefold higher EHQ than ECat (Fig. 3) . The relatively similar levels of 2EP and 4EP substrate loss by rat and human lung microsomes also indicated adequate viability of these human tissue samples.
Microsomal metabolism of EB to dihydroxyethylbenzenes. Because of the relatively high conversions of EPs to dihydroxyethylbenzenes in the initial Part II experiments, described in the section above, 7mM EB was incubated with liver and lung microsomes of the three species and the formation of EHQ and ECat determined. Incubation of 
Note. Data are average of three replicates for each concentration and species. Most of the coefficient of variation was 10% with the exception of few higher values. 
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microsomes with high concentration of EB was needed to determine whether the low amounts of EPs observed in the Part I experiments were due to very little metabolism or the transient nature of these metabolites, that were rapidly metabolized to dihydroxyethylbenzenes. Neither EHQ nor ECat was detected in any of the incubations above the limit of detection (data not shown) supporting the hypothesis that the formed EPs were probably rapidly further metabolized to dihydroxylated products. Metabolism of EB to 1PE, 2EP and 4EP by liver and lung microsomes of the three species remained the same when introduced either to the incubation mixture as vapor or as a solution in PG (Tables 1-3 ).
Part III: Rate of Microsomal Metabolism of EB to 1PE, AcPh, EHQ, and ECat
After determining the difference in the extent of metabolism of EB by the liver and lung microsomes obtained from rat, mouse and human in Parts I and II, Part III experiments were conducted to determine the difference in the rate of metabolism of EB. This was carried out by determining the kinetics of the formation of nonreactive (1PE, AcPh) and reactive (2,5EQ via intermediate 2EP and EHQ and 3,4EQ via intermediate 4EP and ECat) metabolites of EB by the rat, mouse, and human liver and lung microsomes.
Comparative levels of metabolite formation. Tables 3 and 4 summarize the amount and percent conversion of EB to the four metabolites of interest (1PE, AcPh, and the GSH-trapped conjugates of 2,5-EQ [2EP-GSH] and 3,4-EQ [4EP-GSH]) formed during 30-min incubations with liver and lung microsomes of mouse, rat, and human. Human lung microsomes failed to produce detectable levels of any of the four metabolites (Table 4 ) consistent with the results of the Part I experiment. 1PE represents the major metabolite formed during microsomal incubations with EB, regardless of species or tissue type (Tables 1-4) . Amounts of 1PE increased with increasing substrate concentrations for all species/microsomes tissue types. 1PE levels were two-to fivefold higher in incubates of mouse lung compared with the levels in rat lung incubations. Levels of 1PE formed in the liver microsomal incubates followed the general rank order of mouse > rat ! human. The greatest disparity in 1PE formation (between species or tissue type) was observed at lowest substrate concentrations. 1PE plateaued at similar levels during incubations with mouse and rat liver microsomes indicating the primary route of EB metabolism (e.g., alkyl-oxidation) in mouse and rat microsomal systems was saturated at the highest substrate concentrations. AcPh was formed at much lower levels than 1PE, and was not detectable in the majority of samples from the rat lung and human liver incubations (Tables 3 and 4) .
A representative chromatogram from the HPLC/MRM/MS analyses of incubates for 2EP-GSH and 4EP-GSH is shown in Figure 4 . Typical time-of-flight mass spectra of 2EP-GSH and 4EP-GSH are shown in Figure 5 . Note that two isomers of the 2EP-GSH adduct were observed in the microsomal incubations. GSH adducts derived from the ring-oxidized EB metabolites (i.e., quinones of EHQ and ECat) were formed at much lower levels than that of alkyl-oxidized 1PE and AcPh metabolites. Molar conversions ranged from 0.0001% (4EP-GSH; rat lung) to 0.6% (2EP-GSH; mouse lung) compared with conversions of EB to 1PE that ranged from 1% (rat lung; 7mM EB) to 58% (mouse lung; 0.22mM EB) ( Table 4 ). The GSH adducts of 2,5EQ (2EP-GSH) were generally formed in higher amounts than GSH adducts of 3,4EQ (4EP-GSH); typically the differences were at least 10-fold (Tables 3 and 4) . Mass amounts of 2EP-GSH formed in incubations with mouse liver microsomes remained constant or decreased slightly and exhibited concentration dependent increase in rat liver (Tables 3). Formation of 2EP-GSH adduct isomers was substantially greater in mouse lung relative to rat lung, and was also higher than either mouse or rat liver (Tables 3 and 4) . Significantly greater total amounts of 2EP-GSH was formed by mouse lung at the lowest substrate concentrations than the higher EB substrate concentrations, similar pattern was observed in the rat lung microsomes (Table 4) .
Kinetics of metabolite formation. Lineweaver-Burk plots were constructed to derive K m and V max values to describe conversion of EB to the major metabolites 1PE and AcPh, and when possible, conversion to the reactive metabolites (i.e., 2EP-GSH and 4EP-GSH) ( Table 5 , Fig. 5) .
Derivation of Michaelis-Menten constants for the metabolism of EB to AcPh, 2EP-GSH, and 4EP-GSH by mouse liver microsomes and EB to 4EP-GSH by human liver microsomes was not possible as the formation of these metabolites was either nearly constant or decreased with increasing EB concentration. As suggested by results in Parts I and II, classic calculation of intrinsic clearance (V max /K m ) indicates that the metabolism of EB to 1PE was the most dominant route and its METABOLISM OF EB BY RAT MOUSE AND HUMAN 359 rate in mouse liver was 3.6-fold higher than rat and 2-fold higher than human liver microsomes (Table 5 ). The rate of metabolism of EB to 2EP-GSH by the liver microsomes was substantially less (~150-570 fold) than 1PE and the rate of formation of 4EP-GSH was 10-fold lower than 2EP-GSH (Tables 5 and 6 ). The rate of formation of 2EP-GSH was in the order of mouse > human > rat and for 4EP-GSH was in the order of rat > human > mouse (Tables 5 and 6 ). The rate of metabolism of EB to 1PE by mouse lung microsomes was 3.4-fold higher than the liver microsomes (V max ¼ 19.50 nmol/min/ mg protein for the lung versus 5.78 nmol/min/mg protein for the liver microsomes) ( Table 5 ). The intrinsic clearance of the formed 1PE by rat lung microsomes (~7-fold lower than mouse lung microsomes) was 1.6-fold faster due to high affinity (K m ¼ 0.07lM for rat vs. 0.77 lM for mouse lung microsomes) and low capacity (6.7-fold lower V max ) of the enzyme.
As mentioned above, K m and V max values could not be derived for metabolites whose rates of formation decreased with increasing substrate levels. However, to provide comparable information for the two reactive metabolites, the velocities of conversion were calculated for each of the six tissue types at the lowest (0.22mM) substrate concentration. Maximum velocities of the formation of reactive metabolites by lung microsomes were ninefold higher in mouse than rat for the formation of 2EP-GSH (0.0404 vs. 0.0043 nmol/min/mg protein for mouse and rat, respectively), with none detected from human microsomes ( Table 6 ). The formation of 4EP-GSH was approximately 70% higher in mouse than rat lung microsomes, again with no detectable metabolite in human microsomes. Similar rank orders of metabolic activity were seen in liver microsomes for 2EP-GSH, with the exception that metabolite levels were fairly similar between rat and human. The velocity of the formation of 4EP-GSH by human liver microsomes was 2-and 10-fold higher than mouse and rat liver microsomes (Table 6) .
DISCUSSION
The present study confirmed that the major in vitro metabolism of EB by microsomes is the formation of 1PE, similar to what has been reported for the rat liver microsomal metabolism by Midorikawa et al. (2004) . The pattern of EB 
Note. Data are average of three replicates for each concentration and species. Most of the coefficient of variation was 10% with the exception of few higher values.
metabolism by rat liver microsomes was similar to their findings with AcPh being the second most prevalent metabolite. Similarly, 2,5-EQ and 3,4-EQ as GSH conjugates were found to be minor metabolites of EB by rats as reported earlier (Engstrom, 1984; Midorikawa et al., 2004) .
A major objective of this study was to compare the pattern of metabolism of EB by rat, mouse, and human liver and lung microsomes. The rate of EB metabolism by mouse liver microsomes was 2-to 10-fold higher than rats; whereas EB metabolism rates by human liver microsomes were similar to rats. These results distinctly demonstrate that mouse liver microsomes are much more active in metabolizing EB than either rat or human liver microsomes.
Both rat and mouse lung microsomes were more active in metabolizing EB than liver microsomes, whereas human lung microsomes did not metabolize EB to any metabolites monitored above the instrumental limit of detection (0.0005-0.0007 lmoles in the reaction mixture). In the case of lung microsomes, the maximum velocity for the mouse was two-to ninefold higher for the metabolism of EB to reactive metabolites (i.e., 2EP-GSH and 4EP-GSH, respectively) than rat. The level of conversion of EB by mouse lung microsomes was consistent with the abundance of Clara cells and higher P450 levels in mouse lungs than rat lungs (Green et al., 2003; Hellmold et al., 1993) . The CYP 1A1 activity in the mouse lung microsomes used in this study was 16-fold higher than rat lung microsomes (Table 7) . Lack of metabolism of EB by human lung microsomes can be explained by the fact that human lungs contain very low levels of Clara cells and P450 (Devereux et al., 1989; Green et al., 2003; Keith et al., 1987; Wheeler and Guenthner, 1991) . The CYP 1A1 activity in human lung microsomes used in this study was only 5.1% of that found in rat and 2.7% of mouse lung microsomes (Table 7) . These levels were~38% of that has been reported for nonsmoker human lung microsomes prepared from fresh tissues obtained within 15 min of lobectomy (Table 7) (Smith et al., 2001) . Percent conversion of EB to ring-hydroxylated metabolites was much lower than what was observed for the alky-hydroxylated metabolites, ranging from 0.0001% (4EP-GSH; rat lung) to 0.6% (2EP-GSH; mouse lung). 2EP-GSH concentrations were typically 10-fold higher than 4EP-GSH. At lower substrate concentrations, more 2EP-GSH formed during incubations with lung microsomes than liver microsomes, for both rats and mice. More 2EP-GSH was formed in incubations with mouse liver microsomes than in incubations with liver microsomes from rat and human.
In case of human lung microsomes, the conversion of EB to ring-hydroxylated metabolites remained below the limit of detection (2EP-GSH < 0.00007% to < 0.002%; 4EP-GSH < 0.0001% to < 0.002% conversion) ( Table 4) . As discussed above, the metabolism of 4EP by human lung microsomes was appreciable (Fig. 3) . However, given the activity of lung microsomes used in this study was~38% of that reported for tissues harvested during surgery (Smith et al., 2001 ), extrapolating these rates by that factor will only bring the conversion of EB to < 0.0002% to < 0.006% (2EP-GSH) and 
FIG. 6.
Lineweaver-Burk plots of the 1PE (A1 and C1), AcPh (A2 and C2) data derived from the incubation of EB with liver and lung microsomes, respectively, and 2EP-GSH (B1) and 4EP-GSH (B2) derived from the incubation of EB with liver microsomes. Lineweaver-Burk plots could not be constructed for mouse liver (AcPh, 2EP-GSH, 4EP-GSH), human liver (4EP-GSH), mouse, and rat lung (2EP-GSH, 4EP-GSH) as the amount of metabolites formed decreased with the increasing EB concentration (suicidal inhibition). All metabolites from the human lung and AcPh from the rat lung microsomal incubations remained below the limit of detection.
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< 0.0003% to < 0.006% (4EP-GSH); much lower conversion by human lung microsomes even when compared with the rat lung microsomes (Table 4) . These reactive metabolite levels in human tissue would still be nondetectable or slightly above the limit of quantification. Because no lung tumors or cancer have been seen in limited studies in workers exposed to high concentrations of EB by Holz et al. (1995) and IARC (2000) or in comprehensive studies in rats (Maltoni et al., 1985; NTP, 1999) , whereas lung tumors were found in mice exposed to EB, the higher formation rate of these reactive metabolites in the mouse would support this metabolic pathway as a contributor to the initiation of lung tumors. The potential role of quinone-type bioactivated metabolites as a driver of tumor formation is supported for a variety of compounds such as acetaminophen, benzene, butylated hydroxytoluene, and estrogen (Baillie, 2006; DeCaprio, 1999; Thompson et al., 1991; Zhang et al., 2001) .
The highest levels of ring-hydroxylated metabolites were formed in incubations with mouse lung microsomes. Interestingly, both mouse and rat lung microsomes (and to a lesser extent, mouse liver microsomes) exhibited decreasing amounts of ring-oxidized metabolite formation with increasing concentrations of EB. The reason for the decrease in metabolite formation shown in Tables 3 and 4 is unclear. One possibility is a noncompetitive inhibition of the enzyme by the substrate or a formed product causing a loss of metabolic activity. Another explanation for the decrease in formed product is cytochrome a Activity in nonsmoker lung microsomes (n ¼ 24) prepared immediately (within~15 min) after removal (20-100 g) during clinically indicated lobectomy of lung tissues devoid of macroscopically visible tumors (Smith et al., 2001) .
b Phenobarbital induced rat liver microsomes analyzed with study tissues as a reference for comparison. P450 suicide inhibition by reactive ring-oxidized metabolite(s). The possible suicide inhibition appears to be isozyme-specific in that generation of alkyl-oxidized metabolites was not similarly decreased with increasing EB substrate concentrations. This observation is consistent with the hypothesis that reactive ring-oxidized metabolites are likely formed by cytochrome P450 2F2, whereas alkyl-oxidized metabolite formation is mediated predominantly through cytochrome P450 2E1. More data is needed in order to characterize this loss of formed product seen with increasing EB substrate concentration. Classic intrinsic clearance values (V max /K m ) could not be derived for the formation of the two reactive metabolites in all six tissue types, due to inhibition observed at the higher substrate concentrations. However, the low-substrate metabolite formation rates in Table 6 can be used for interspecies extrapolations. Venkatakrishnan et al. (2001) discuss the use of first-order metabolism rates (''model-independent in vitro halflife approach''), obtained from very low-level substrate incubations (~1lM) in which a large percentage of the substrate is metabolized, as a means of predicting in vivo metabolic clearance. Several authors have utilized this approach successfully for this purpose (Lave et al., 1997; Naritomi et al., 2001; Obach, 1999; Riley et al., 2005) . In the case of 2EP-GSH and 4EP-GSH formation, the precursor metabolites (2EP and 4EP) are formed at < 0.3% of the EB substrate (Tables 1 and 2 ). These low lMolar phenolic metabolite concentrations would correspond to the conditions discussed by Obach (1999) and others. Also, because the formation of 2EP-GSH and 4EP-GSH from EB involves four metabolic steps, a simple first-order rate is probably the most relevant means of calculating intrinsic clearance values from each of the six tissue types used in these experiments.
Although ring-oxidized metabolites accounted for a relatively small fraction of overall EB metabolism, its selective elevation in mouse lung microsomes is nonetheless consistent with the hypothesized mode of action for the observed preferential toxicity of EB to mouse lung. The significantly reduced ability of rat and human microsomes to form potential reactive ringoxidized metabolites relative to mice also supports the hypothesis that these metabolites are critical to the specific lung tumorigenicity of EB in mice and lack of it in rats and in exposed workers (Holz et al., 1995; IARC, 2000; NTP, 1999) . 
